Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) EBITDA Margin (2016)

Rocket Pharmaceuticals' EBITDA Margin history spans 2 years, with the latest figure at 1303.83% for Q3 2018.

  • For Q3 2018, EBITDA Margin changed N/A year-over-year to 1303.83%; the TTM value through Jun 2019 reached 9414.03%, changed N/A, while the annual FY2015 figure was 1658.21%, 87209.0% up from the prior year.
  • EBITDA Margin for Q3 2018 was 1303.83% at Rocket Pharmaceuticals, down from 4203.05% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 4850.24% in Q1 2016 and bottomed at 1303.83% in Q3 2018.